Immunotherapy drug durvalumab is a game-changer for bladder cancer patients, keeping 85% surgery-free after one year compared to just 60% with standard treatment. Avoiding bladder removal means dodging devastating side effects like lifelong stoma bags that upend daily life. This breakthrough, presented at the world's largest cancer conference, has real potential to become the new standard of care.